CareDx Q1 revenue $84.7M (+18% YoY); GAAP net loss narrows to $10.4M; non-GAAP net income $5.4M

CareDx, Inc.

2025-Q1 EPS reported -$0.19 revenue$84,685,000

Revenue $84.7M (+18% YoY); testing services revenue $61.9M (+15%), volume ~47,100 (+12% YoY).
GAAP net loss $10.4M ($0.19 loss per share) vs $19.9M ($0.38) prior year; non-GAAP net income $5.4M ($0.09 diluted).
Adjusted EBITDA $4.6M vs loss $1.9M; cash $231M, no debt.
Reaffirms FY2025 revenue guidance $365-375M, adjusted EBITDA $29-33M; 2027 targets $500M rev, $100M EBITDA.
Launched AlloSure Heart for pediatric and AlloSure Kidney for SPK; presented AlloHeme data at TANDEM and EBMT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.